SuperX Announces an Update on the Progress of Share Repurchases Program, to Demonstrate Confidence in Long-Term Growth Value

SuperX Announces an Update on the Progress of Share Repurchases Program, to Demonstrate Confidence in Long-Term Growth Value

SINGAPORE, Sept. 9, 2026 /PRNewswire/ -- SuperX AI Technology Limited (NASDAQ: SUPX) ("SuperX" or the "Company"), a Nasdaq-listed full-stack AI infrastructure solutions provider, today announced an update on the progress of its share repurchase...

Cheche Group Announces Proposed Strategic Investment in Global Residential Energy Storage Business, Advancing Green Mobility to Green Energy Strategy

Cheche Group Announces Proposed Strategic Investment in Global Residential Energy Storage Business, Advancing Green Mobility to Green Energy Strategy

Proposed strategic investment in Long Way Fortune's residential solar-plus-storage business, with potential to increase ownership over time, supporting Cheche's new "Green Mobility + Green Energy" two-pillar strategy BEIJING, Sept. 9, 2026...

Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer

Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer

Multicenter study to evaluate paxalisib plus gemcitabine for children and young adults with recurrent or progressive AT/RT, where no approved therapies currently exist SYDNEY, Sept. 9, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA)...

Robo.ai Announces Proposed Establishment of Alif Maritec, a Marine Security and Intelligent Maritime Infrastructure Company

Robo.ai Announces Proposed Establishment of Alif Maritec, a Marine Security and Intelligent Maritime Infrastructure Company

Wholly owned subsidiary of Alif Holding to focus on maritime protection, smart ports, underwater intelligence and critical infrastructure protection; Dr. Jasem Al-Mansory expected to serve as Chairman ABU DHABI, UAE, Sept. 9, 2026 /PRNewswire/ --...

Youlife Group, Inc. Announces Participation in the Skyline Signature Series Webinar

Youlife Group, Inc. Announces Participation in the Skyline Signature Series Webinar

SHANGHAI, Sept. 9, 2026 /PRNewswire/ -- Youlife Group Inc. ("Youlife" or the "Company") (NASDAQ: YOUL), a leading blue-collar lifetime service provider in China, is pleased to announce that Stanley Yang, Chief Strategy Officer, will be delivering a...

Thoma Bravo Announces Strategic Growth Investment in Tanda

Thoma Bravo Announces Strategic Growth Investment in Tanda

Investment to accelerate Tanda's product innovation and global growth BRISBANE, Australia and SAN FRANCISCO, Sept. 9, 2026 /PRNewswire/ -- Thoma Bravo, the world's largest software-focused investment firm, today announced a strategic growth...

Accro Bioscience Announces IND Clearance from NMPA for Phase II/III Clinical Trial of AC-201, a Highly Selective TYK2/JAK1 Inhibitor for the Treatment of Non-Segmental Vitiligo

Accro Bioscience Announces IND Clearance from NMPA for Phase II/III Clinical Trial of AC-201, a Highly Selective TYK2/JAK1 Inhibitor for the Treatment of Non-Segmental Vitiligo

NEW YORK and SUZHOU, China, Sept. 8, 2026 /PRNewswire/ -- Accro Bioscience (Suzhou) Limited ("Accro") today announced that Shanghai Fosun Pharmaceutical Industrial Development Company Limited ("Fosun Pharma Industrial"), a subsidiary of its partner...

Alebund Pharmaceuticals Announces FDA Clearance of IND Application for AP308 for the Treatment of IgA Nephropathy

Alebund Pharmaceuticals Announces FDA Clearance of IND Application for AP308 for the Treatment of IgA Nephropathy

SHANGHAI, Sept. 8, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; HKEX: 09637), a renal-focused biopharmaceutical company, today announced that it has recently received clearance from the U.S. Food and...

Kelun-Biotech's Partner Windward Bio Announces Positive Phase 2 Results of SKB378/WIN378 in Asthma, and Initiates Phase 3 Study

Kelun-Biotech's Partner Windward Bio Announces Positive Phase 2 Results of SKB378/WIN378 in Asthma, and Initiates Phase 3 Study

The POLARIS-1 study enrolled 147 patients with uncontrolled, moderate-to-severe asthma, and the interim analysis was conducted on the first 98 patients. The analysis demonstrated a half-life of up to 75 days, with clinical effects consistent with...

Ascletis Announces Initiation of Phase I Study in U.S. for Oral Amylin Receptor Peptide Agonist ASC36 for the Treatment of Obesity

Ascletis Announces Initiation of Phase I Study in U.S. for Oral Amylin Receptor Peptide Agonist ASC36 for the Treatment of Obesity

- This trial marks the fourth Phase I peptide study for Ascletis this year. - ASC36 oral tablets achieved absolute oral bioavailability of 6% to 8% at steady state in non-human primate (NHP) studies utilizing Ascletis' proprietary Peptide Oral...

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...
  • 103
  • menu
    menu